Cesium cessation? An advantage of pathogen reduction treatments

Transfusion

Volumn 51, Issue 7, 2011, Pages 1369-1376

  Mintz, Paul D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CESIUM CHLORIDE; DNA; FRESH FROZEN PLASMA;

BLOOD COMPONENT; BLOOD RADIATION; CELL PROLIFERATION; DNA DAMAGE; ERYTHROCYTE; GRANULOCYTE; HEALTH CARE COST; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NEUTROPHIL; PERIPHERAL BLOOD MONONUCLEAR CELL; REVIEW; THROMBOCYTE; TRANSFUSION ASSOCIATED GRAFT VERSUS HOST DISEASE; VIRUS REACTIVATION;

BLOOD TRANSFUSION; CESIUM RADIOISOTOPES; GRAFT VS HOST DISEASE; HUMANS; LEUKOCYTE REDUCTION PROCEDURES; LEUKOCYTES; PRACTICE GUIDELINES AS TOPIC;

EID: 79960187192     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2011.03201.x     Document Type: Review

References (69)

1. Schroeder ML,. Transfusion-associated graft-versus-host disease. Br J Haematol 2002; 117: 275-87. (Pubitemid 34451142)
2. Graw RG Jr, Buckner CD, Whang-Peng J, Leventhal BG, Krüger G, Berard C, Henderson ES,. Complications of bone-marrow transplantation graft-versus-host disease resulting from chronic-myelogenous-leukemia leucocyte transfusions. The Lancet 1970; 296: 338-41.
3. Pelszynski MM, Moroff G, Luban NL, Taylor BJ, Quinones RR,. Effect of gamma irradiation of red blood cell units on T-cell inactivation as assessed by limiting dilution analysis: implications preventing transfusion-associated graft-versus-host disease. Blood 1994; 83: 1683-9. (Pubitemid 24081586)
4. Luban NL, Drothler D, Moroff G, Quinones R,. Irradiation of platelet components: inhibition of lymphocyte proliferation assessed by limiting-dlution analysis. Transfusion 2000; 40: 348-52. (Pubitemid 30171687)
5. Food and Drug Administration. Memorandum: recommendations regarding license amendments and procedures for gamma irradiation of blood products (July 22, 1993). Rockville, MD: CBER Office of Communication, Outreach, and Development, 1993. [cited 2011 Apr 8]. Available from: URL http://www.fda.gov/ downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/ OtherRecommendationsforManufacturers/MemorandumtoBloodEstablishments/UCM062815. pdf
6. Carson TH, editor. Standards for blood banks and transfusion services. 27th ed. Bethesda (MD): American Association of Blood Banks; 2011.
7. Wieding JU, Vehmeyer K, Dittman J, HIddemann W, Kohler K,. Contamination of fresh-frozen plasma with viable white cells and proliferable stem cells. Transfusion 1994; 34: 185-6.
8. Akahoshi M, Takanashi M, Masuda M, Yamashita H, Hidano A, Hasegawa K, Kasajima T, Shimizu M, Motoji T, Oshimi K, Mizoguchi H,. A case of transfusion-associated graft-versus-host disease not prevented by white cell-reduction filters. Transfusion 1992; 32: 169-72.
9. Hayashi H, Nishiuchi T, Tamura H, Takeda K,. Transfusion-associated graft-versus-host disease caused by leukocyte-filtered stored blood. Anesthesiology 1993; 79: 1419-21. (Pubitemid 24005790)
10. U.S. Department of Health and Human Services. The 2009 nationwide blood collection and utilization survey report. Washington, D.C.: U.S. Department of Health and Human Services, Office of the Assistant Secretary for Health, 2011.
11. Borchardt RW,. Strategy for the security and use of cesium-137 chloride sources. SECY-08-0184. Rockville, MD: Nuclear Regulatory Commission, 2008. [cited 2011 Apr 8]. Available from: URL http://www.nrc.gov/reading-rm/ doccollections/commission/secys/2008/secy2008-0184/2008-0184scy.pdf
12. Jankovich JP,. Overview of the U.S. nuclear regulatory commission's initiatives on the use of cesium-137 chloride sources. 2010. [cited 2011 Apr 8]. Available from: URL http://pbadupws.nrc.gov/docs/ML1031/ML103190080.pdf
13. Gorlin JB, Mintz PD,. Transfusion-associated graft-versus-host disease. In:, Mintz PD, editor. Transfusion therapy: clinical principles and practice. 3rd ed. Bethesda (MD): American Association of Blood Banks; 2011. p. 643-63.
14. Levine JE, Ferrara JL,. Transfusion-associated graft-versus-host disease. In:, Simon TL, Snyder EL, Solheim BG, Stowell CP, Strauss RG, Petrides M, editors. Rossi's principles of transfusion medicine. 4th ed. Bethesda (MD): American Association of Blood Banks; 2009. p. 847-57.
15. Luban NL, Wong EC,. Irradiated products. In:, Hillyer CD, Silberstein LE, Ness PM, Anderson KC, Roback JD, editors. Blood banking and transfusion medicine: basic principles & practice. 2nd ed. Philadelphia (PA): Churchill Livingstone Elsevier; 2007. p. 397-409.
16. U.S. Nuclear Regulatory Commission. Holders of material licenses authorized to possess radioactive material quantities of concern. [cited 2011 Apr 8]. Available from: URL http://www.nrc.gov/reading-rm/doc-collections/ enforcement/security/index.html#6
17. Carpenter C,. Request for comments on the draft policy statement on the protection of cesium-137 chloride sources and notice of public meeting. Federal Register. 2010 June 29; 75: 37483-8.
18. Miller CL,. Update on staff efforts to work with federal partners on voluntary security initiatives for radioactive materials. 2010. [cited 2011 Apr 8]. Available from: URL http://www.nrc.gov/reading-rm/doc-collections/ commission/secys/2010/secy2010-0036/2010-0036scy.html
19. Wiggins JT,. International radioactive source security efforts. 2010. [cited 2011 Apr 8]. Available from: URL http://www.nrc.gov/reading-rm/doc- collections/commission/secys/2010/secy2010-0066/2010-0066scy.html
20. U.S. Nuclear Regulatory Commission. The 2010 radiation source protection and security task force report. 2010. [cited 2011 Apr 8]. Available from: URL http://www.nrc.gov/security/byproduct/2010-task-force-report.pdf
21. AABB. Nuclear regulatory commission public meeting on cesium chloride uses, including blood irradiators. 2008. [cited 2011 Apr 8]. Available from: URL http://www.aabb.org/events/government/public/Pages/nrcmeeting092908.aspx
22. U.S. Nuclear Regulatory Commission. Licensing of medical, industrial, and academic uses of nuclear materials. 2010. [cited 2011 Apr 8]. Available from: URL http://www.nrc.gov/materials/miau/licensing.html
23. U.S. Nuclear Regulatory Commission. Task force on radiation source protection and security. 2011. [cited 2011 Apr 8]. Available from: URL http://www.nrc.gov/security/byproduct/task-force.html
24. National Academies. Government should spur replacement of radioactive cesium chloride in medical and research equipment; alternatives could lower potential for theft and misuse. 2008. [cited 2011 Apr 8]. Available from: URL http://www8.nationalacademies.org/onpinews/newsitem.aspx?RecordID=11976
25. NRC staff: preserved status quo on blood irradiators. ABC Newsletter 2008; 45: 9-10.
26. Tadokoro K, Reesink HW, Panzer S, Chabanel A, Santailler G, Guérin T, Socquet D, David B, Labrune JL, Lin CK, Tsoi WC, Letowska M, Antoniewicz-Papis J, Naniewicz J, Dudziak K, Lachert E, Lozano M, Schneider K, Snyder EL, Champion MH,. Problems with irradiators. Snyder commentary. Vox Sang 2010; 98: 78-84.
27. Moroff G, Luban NL,. The irradiation of blood and blood components to prevent graft-versus-host disease: technical issues and guidelines. Transfus Med Rev 1997; 11: 15-26. (Pubitemid 27083612)
28. Friedman KD, McDonough WC, Cimino DF,. The effect of prestorage gamma irradiation on posttransfusion red blood cell recovery [abstract]. Transfusion 1991; 31 (Suppl): 50S.
29. Davey RJ, McCoy NC, Yu M, Sullivan JA, Spiegel DM, Leitman SF,. The effect of prestorage irradiation on posttransfusion red cell survival. Transfusion 1992; 32: 525-8.
30. Moroff G, Holme S, AuBuchon JP, Heaton WA, Sweeney JD, Friedman LI,. Viability and in vitro properties of AS-1 red cells after gamma irradiation. Transfusion 1999; 39: 128-34. (Pubitemid 29085132)
31. Card RT, Mohandas N, Mollison PL,. Relationship of post-transfusion viability to deformability of stored red cells. Br J Haematol 1983; 53: 237-40. (Pubitemid 13171496)
32. Cicha I, Suzuki Y, Tateishi N, Shiba M, Muraoka M, Tadokoro K, Maeda M,. Gamma-ray-irradiated red blood cells stored in mannitol-adenine-phosphate medium: rheological evaluation and susceptibility to oxidative stress. Vox Sang 2000; 79: 75-82.
33. Relevy H, Koshkaryev A, Manny N, Yedgar S, Barshtein G,. Blood banking-induced alteration of red blood cell flow properties. Transfusion 2008; 48: 136-46.
34. Barshtein G, Manny N, Yedgar S,. Circulatory risk in the transfusion of red blood cells with impaired flow properties induced by storage. Transfus Med Rev 2011; 25: 24-35.
35. Davey RJ, Stec NM, Lee JL, Leitman SF,. The effect of prestorage leukocyte reduction on the irradiation-induced red cell storage lesion. Transfusion 1995; 35: 55S.
36. Ramirez AM, Woodfield DG, Scott R, McLachlan J,. High potassium levels in stored irradiated blood. Transfusion 1987; 27: 444-5.
37. Rivet C, Baxter A, Rock G,. Potassium levels in irradiated blood [letter]. Transfusion 1989; 29: 185.
38. Mintz P, Anderson G,. Effect of gamma irradiation on the in vivo recovery of stored red blood cells. Ann Clin Lab Sci 1993; 23: 216-20. (Pubitemid 23161873)
39. Wagner SJ, Myrup AC,. Prestorage leucoreduction improves several in vitro red cell storage parameters following gamma irradiation. Transfus Med 2006; 16: 261-5. (Pubitemid 44127877)
40. Janatpour K, Denning L, Nelson K, Betlach B, MacKenzie M, Holland P,. Comparison of X-ray versus gamma irradiation of CPDA-1 red cells. Vox Sang 2005; 89: 215-9. (Pubitemid 41641101)
41. Hall TL, Barnes A, Miller JR, Bethencourt DM, Nestor L,. Neonatal mortality following transfusion of red cells with high plasma potassium levels. Transfusion 1993; 33: 606-9. (Pubitemid 23210800)
42. Fung MK, Roseff SD, Vermoch KL,. Blood component preferences of transfusion services supporting infant transfusions: a University Healthsystem Consortium benchmarking study. Transfusion 2010; 50: 1921-5.
43. Strauss RG,. Red blood cell storage and avoiding hyperkalemia from transfusions to neonates and infants. Transfusion 2010; 50: 1862-5.
44. Read EJ, Kodis C, Carter CS, Leitman SF,. Viability of platelets following storage in the irradiated state. A pair-controlled study. Transfusion 1988; 48: 446-50. (Pubitemid 18260651)
45. Harris SB, Hillyer CD,. Blood manufacturing: component preparation, storage, and transportation. In:, Hillyer CD, Silberstein LE, Ness PM, Anderson KC, Roback JD, editors. Blood banking and transfusion medicine: basic principles & practice. 2nd ed. Philadelphia (PA): Churchill Livingstone Elsevier; 2007. p. 183-204.
46. Tynngard N, Studer M, Lindahl TL, Trinks M, Berlin G,. The effect of gamma irradiation on the quality of apheresis platelets during storage for 7 days. Transfusion 2008; 48: 1669-75.
47. King KE, Ness PM,. How do we prevent transfusion-associated graft-versus-host disease in children? Transfusion 2011; 51: 916-20.
48. Leitman S, Tisdale J, Bolan C, Popovsky MA, Klippel JH, Balow JE, Boumpas DT, Illei GG,. Transfusion-associated GVHD after fludarabine therapy in a patient with systemic lupus erythematosus. Transfusion 2003; 43: 1667-71. (Pubitemid 37518072)
49. Ambruso DR, Thurman G, Tran K, Marschner S, Gathof B, Janetzko K, Goodrich RP,. Generation of neutrophil priming activity by cell-containing blood components treated with pathogen reduction technology and stored in platelet additive solutions. Transfusion 2011; 51: 1220-7.
50. Ferrieu C, Ballester B, Mathieu J, Drouet E,. Flow cytometry analysis of gamma-radiation-induced Epstein-Barr virus reactivation in lymphocytes. Radiat Res 2003; 159: 268-73. (Pubitemid 36182406)
51. Little J,. Mechanisms of malignant transformation. Carcinogenesis 1985; 10: 337-53.
52. Leitman SF, Holland P,. Irradiation of blood products: indications and guidelines. Transfusion 1985; 25: 293-300.
53. Fast LD, DiLeone G, Marschner S,. Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation. Transfusion 2011; 51: 1397-404.
54. Mintz PD, Wehrli G,. Irradiation eradication and pathogen reduction. Ceasing cesium irradiation of blood products. Bone Marrow Transplant 2009; 44: 205-11.
55. Marschner S, Fast LD, Baldwin WM, Slichter SJ, Goodrich RP,. White blood cell inactivation after treatment with riboflavin and ultraviolet light. Transfusion 2010; 50: 2489-98.
56. Lin L, Corash L, Osselaer JC,. Protection against TA-GVHD due to platelet transfusion by using pathogen inactivation with the INTERCEPT Blood System - gamma irradiation is not the only answer. Haematologica 2010; 95 (Extra): 86-93.
57. Fast L, DiLeone G, Cardarelli G, Li J, Goodrich R,. Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag2-/-gamma c-/- double knockout mice. Transfusion 2006; 46: 1553-60. (Pubitemid 44326331)
58. Cazenave JP, Folléa G, Bardiaux L, Boiron JM, Lafeuillade B, Debost M, Lioure B, Harousseau JL, Tabrizi R, Cahn JY, Michallet M, Ambruso D, Schots R, Tissot JD, Sensebé L, Kondo T, McCullough J, Rebulla P, Escolar G, Mintz P, Heddle NM, Goodrich RP, Bruhwyler J, Le C, Cook RJ, Stouch B,; for members of the Mirasol Clinical Evaluation Study Group. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010; 50: 2362-75.
59. Cherrier-De Wilde S,. Luxembourg: Mirasol platelets. In:, AuBuchon JP, Prowse CV, editors. Pathogen inactivation: the penultimate paradigm shift. Bethesda (MD): American Association of Blood Banks Press; 2010. p. 217-29.
60. Goodrich RP, Doane S, Reddy HL,. Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products. Biologicals 2010; 38: 20-30.
61. Cancelas JA, Rugg N, Fletcher D, Pratt PG, Worsham DN, Dunn SK, Marschner S, Reddy HL, Goodrich RP,. In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood. Transfusion 2011; 51: 1460-8.
62. Grass JA, Hei DJ, Metchette K, Cimino GD, Wiesehah GP, Corash L, Lin L,. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 1998; 91: 2180-8. (Pubitemid 28185525)
63. Grass JA, Wafa T, Reames A, Wages D, Corash L, Ferrara JL, Lin L,. Prevention of transfusion-associated graft versus host disease (TA-GVHD) by photochemical treatment (PCT). Blood 1999; 93: 3140-7. (Pubitemid 29200809)
64. van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Klüter H, Vermeij H, Kappers-Klunne M, de Greef G, Laforet M, Lioure B, Davis K, Marblie S, Mayaudon V, Flament J, Conlan M, Lin L, Metzel P, Buchholz D, Corash L,. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 101: 2426-33. (Pubitemid 36302092)
65. Cazenave JP, Isola H, Waller C, Mendel I, Kientz D, Laforêt M, Raidot JP, Kandel G, Wiesel ML, Corash L,. Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period. Transfusion 2011; 51: 622-9.
66. Lin L, Stassinopoulos A, Corash L,. Cumulative clinical data of INTERCEPT Blood System for platelets demonstrate ability to replace gamma irradiation in routine clinical use for TA-GVHD prevention [abstract]. ISBT meeting. June 2011; 264.
67. Benjamin RJ, McCullough J, Mintz PD, Snyder E, Spotnitz WD, Rizzo RJ, Wages D, Lin JS, Wood L, Corash L, Conlan MG,. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients. Transfusion 2005; 45: 1739-49. (Pubitemid 43923901)
68. Rios JA, Hambleton J, Viele M, Rugg N, Sindermann G, Greenwalt T, Wages D, Cook D, Corash L,. Viability of red cells prepared with S-303 pathogen inactivation treatment. Transfusion 2006; 46: 1778-86. (Pubitemid 44435731)
69. Cancelas JA, Dumont LJ, Rugg N, Szczepiorkowski ZM, Herschel L, Siegel A, Pratt PG, Worsham DN, Erikson A, Propst M, North A, Sherman CD, Mufti NA, Reed WF, Corash L,. Stored red blood cell viability is maintained after treatment with a second generation S-303 pathogen inactivation process. Transfusion 2011. Doi: 10.1111/j.1537-2995.2011.03163.x.